Vir Biotechnology, Inc. (VIR)
Chart Events
Performance Outlook
| Previous Close | 39.67 |
| Open | 38.54 |
| Bid | 41.13 x 900 |
| Ask | 41.30 x 1200 |
| Day's Range | 38.52 - 42.36 |
| 52 Week Range | 25.31 - 141.01 |
| Volume | 962,303 |
| Avg. Volume | 1,753,225 |
| Market Cap | 5.377B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -14.64 |
| Earnings Date | Feb 25, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 80.20 |
Fair Value
Related Research
- Motley Fool
Vir Biotechnology and GlaxoSmithKline Expand Their COVID Partnership to Flu
Last year, Vir Biotechnology (NASDAQ: VIR) and GlaxoSmithKline (NYSE: GSK) partnered up to develop Vir's coronavirus antibody treatment. The London-based pharma must have liked what it saw in Vir, because GlaxoSmithKline recently signed on to develop more drugs developed by Vir. In this video from Motley Fool Live, recorded on Feb. 22, Fool.com contributors Brian Orelli and Keith Speights discuss the deal, which covers treatments and preventions for the flu and other viral infections, and what it means for Vir's future.
- MarketWatch
NIH stops clinical trials for two experimental antibody COVID-19 treatments
The National Institutes of Health said Thursday that it stopped enrollment in two clinical trials evaluating experimental COVID-19 therapies after discovering they likely do not provide a benefit to hospitalized patients. The treatment candidates are GlaxoSmithKline and Vir Biotechnology Inc.'s monoclonal antibody therapy and the privately held Brii Biosciences Inc.'s monoclonal antibody cocktail. Vir told investorson Thursday that the NIH had notified the company about stopping the trial. There were no safety concerns for either therapy. Over the past year, GSK's stock is down 20.0% and shares of Vir tumbled 9.4%, while the broader S&P 500 has rallied 20.4%.
- Zacks
Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & More
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Vir (VIR) and KemPharm, Inc. (KMPH).
